Verb Technology Company, Inc. (VERB), Reckitt Benckiser Group plc (RBGLY) & Omnicell, Inc. (OMCL) - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action

NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

Verb Technology Company, Inc. (NASDAQ: VERB)
Class Period: January 3, 2018 - May 2, 2018
Deadline: September 9, 2019
For more info: www.bgandg.com/verb
The complaint alleges that on January 3, 2018, Verb revealed a purported agreement with Oracle America, Inc. (the “Oracle Agreement”) and filed Form 8-K with the United States Securities and Exchange Commission omitting the text of the agreement itself. The complaint continues to allege that throughout the Class Period, Verb continued to hype this relationship. During this time, Verb stock price increased over 200% up from $0.12 per share on January 3, 2018 to $2.70 on April 19, 2018.

Reckitt Benckiser Group plc (OTCMKT: RBGLY) 
Class Period: July 28, 2014 - April 9, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/rbgly
The complaint alleges that before and throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material adverse information. The complaint alleges that Reckitt was involved in a scheme that generated over $3 billion in proceeds enabling opiate abuse among U.S. consumers and mislead investors and the public concerning the health and safety risks of Suboxone Film, its new key opiate product. Specifically, the complaint alleges that Reckitt senior executives planned to switch prescribers from Suboxone Tablets to its Suboxone Film, which had similar active ingredients to Suboxone Tablets, but is dispensed by a thin film placed under the tongue and stored in single-use foil wrappings. In order to prevent generic competition, the company created a marketing campaign to hype the purported safety benefits of Suboxone Film over Suboxone Tablets. The complaint continues to allege that the campaign was fabricating safety concerns of existing treatments, hoping to delay the entry and approval of generics for Suboxone Tablets. As a result, the sales of Suboxone Film grew. From 2010 and 2014, Reckitt revenues from sales of the drug rose to over $840 million annually. As a result of defendants’ false and misleading statements and/or omissions regarding the alleged scheme, Reckitt ADSs traded at artificially inflated prices.

Omnicell, Inc. (NASDAQ: OMCL)
Class Period: October 25, 2018 - July 11, 2019
Deadline: September 16, 2019
For more info: www.bgandg.com/omcl
The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Omnicell recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) consequently, the Company would be required to write-off certain inventory; (5) Omnicell misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]